Clinical Trials

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti CTLA-4 Monoclonal Antibody in Patients with Advanced Cancer and Select Tumor Types (CTMS# 19-0008)

Cancer Type

Solid Tumor

ClinicalTrials.gov Identifier

NCT03860272

Principal Investigator

Daruka Mahadevan, MD, PhD

For more information about this study
View Details

About This Study

This study is an open-label, Phase 1/2, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181) monotherapy and in combination with a human monoclonal IgG4 antibody (AGEN2034), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors. This study will also determine the RP2D of AGEN1181 monotherapy and in combination with AGEN2034.